These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1345 related items for PubMed ID: 21571593

  • 1. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
    Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA, TRANSFORMS Study Group.
    Lancet Neurol; 2011 Jun; 10(6):520-9. PubMed ID: 21571593
    [Abstract] [Full Text] [Related]

  • 2. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
    Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L, TRANSFORMS Study Group.
    N Engl J Med; 2010 Feb 04; 362(5):402-15. PubMed ID: 20089954
    [Abstract] [Full Text] [Related]

  • 3. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
    Devonshire V, Havrdova E, Radue EW, O'Connor P, Zhang-Auberson L, Agoropoulou C, Häring DA, Francis G, Kappos L, FREEDOMS study group.
    Lancet Neurol; 2012 May 04; 11(5):420-8. PubMed ID: 22494956
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis.
    Agashivala N, Kim E.
    Clin Ther; 2012 Jul 04; 34(7):1583-90. PubMed ID: 22749258
    [Abstract] [Full Text] [Related]

  • 5. Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS.
    Meng X, Chin PS, Hashmonay R, Zahur Islam M, Cutter G.
    Contemp Clin Trials; 2015 Mar 04; 41():69-74. PubMed ID: 25545026
    [Abstract] [Full Text] [Related]

  • 6. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, von Rosenstiel P, Lublin FD.
    Lancet Neurol; 2014 Jun 04; 13(6):545-56. PubMed ID: 24685276
    [Abstract] [Full Text] [Related]

  • 7. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS.
    Cohen JA, Barkhof F, Comi G, Izquierdo G, Khatri B, Montalban X, Pelletier J, Eckert B, Häring DA, Francis G.
    J Neurol; 2013 Aug 04; 260(8):2023-32. PubMed ID: 23632946
    [Abstract] [Full Text] [Related]

  • 8. Oral fingolimod (FTY720) for relapsing multiple sclerosis.
    Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW, FTY720 D2201 Study Group.
    N Engl J Med; 2006 Sep 14; 355(11):1124-40. PubMed ID: 16971719
    [Abstract] [Full Text] [Related]

  • 9. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
    Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Huang V, Kappos L, RADIANCE Trial Investigators.
    Lancet Neurol; 2019 Nov 14; 18(11):1021-1033. PubMed ID: 31492652
    [Abstract] [Full Text] [Related]

  • 10. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group.
    N Engl J Med; 2010 Feb 04; 362(5):387-401. PubMed ID: 20089952
    [Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
    Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Ding N, Cohen JA, SUNBEAM Study Investigators.
    Lancet Neurol; 2019 Nov 04; 18(11):1009-1020. PubMed ID: 31492651
    [Abstract] [Full Text] [Related]

  • 12. Fingolimod for relapsing-remitting multiple sclerosis.
    La Mantia L, Tramacere I, Firwana B, Pacchetti I, Palumbo R, Filippini G.
    Cochrane Database Syst Rev; 2016 Apr 19; 4(4):CD009371. PubMed ID: 27091121
    [Abstract] [Full Text] [Related]

  • 13. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis.
    Barkhof F, de Jong R, Sfikas N, de Vera A, Francis G, Cohen J, TRANSFORMS study group.
    Mult Scler; 2014 Nov 19; 20(13):1704-13. PubMed ID: 24812043
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States.
    Lee S, Baxter DC, Limone B, Roberts MS, Coleman CI.
    J Med Econ; 2012 Nov 19; 15(6):1088-96. PubMed ID: 22583065
    [Abstract] [Full Text] [Related]

  • 15. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
    Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, Stubinski B, Uitdehaag B, REGARD study group.
    Lancet Neurol; 2008 Oct 19; 7(10):903-14. PubMed ID: 18789766
    [Abstract] [Full Text] [Related]

  • 16. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study.
    Cohen JA, Khatri B, Barkhof F, Comi G, Hartung HP, Montalban X, Pelletier J, Stites T, Ritter S, von Rosenstiel P, Tomic D, Kappos L, TRANSFORMS (TRial Assessing injectable interferoN vS. FTY720 Oral in RRMS) Study Group.
    J Neurol Neurosurg Psychiatry; 2016 May 19; 87(5):468-75. PubMed ID: 26111826
    [Abstract] [Full Text] [Related]

  • 17. Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.
    Roskell NS, Zimovetz EA, Rycroft CE, Eckert BJ, Tyas DA.
    Curr Med Res Opin; 2012 May 19; 28(5):767-80. PubMed ID: 22462530
    [Abstract] [Full Text] [Related]

  • 18. Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis.
    Chitnis T, Arnold DL, Banwell B, Brück W, Ghezzi A, Giovannoni G, Greenberg B, Krupp L, Rostásy K, Tardieu M, Waubant E, Wolinsky JS, Bar-Or A, Stites T, Chen Y, Putzki N, Merschhemke M, Gärtner J, PARADIGMS Study Group.
    N Engl J Med; 2018 Sep 13; 379(11):1017-1027. PubMed ID: 30207920
    [Abstract] [Full Text] [Related]

  • 19. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
    Singer B, Ross AP, Tobias K.
    Int J Clin Pract; 2011 Aug 13; 65(8):887-95. PubMed ID: 21679286
    [Abstract] [Full Text] [Related]

  • 20. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
    Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA, CARE-MS I investigators.
    Lancet; 2012 Nov 24; 380(9856):1819-28. PubMed ID: 23122652
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 68.